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Abstract: Persistent infection of high-risk (HR) human papillomavirus (HPV) infection has been widely associated with 
cervical cancer. Monitoring HPV infection is therefore an important step against cervical cancer development. The 
DiagCor GenoFlow Human Papillomavirus Array Test (GenoFlow) is a novel HPV test based on PCR and “Flow-
through” hybridization that can identify 33 HPV subtypes in 3 hours. In the present study, the GenoFlow Test was 
evaluated by comparing the genotyping results of 100 samples with Roche Linear Array HPV Genotyping Test (LA). The 
tests showed good agreement in detection of HPV-positive samples (concordance rate=95%, Cohen’s Kappa=0.896), with 
good agreement in detection of HR HPVs (Cohen’s Kappa=0.876). The GenoFlow Test showed high sensitivity (95%), 
high specificity (95%), low false positive rate (3.33%) and low false negative rate (7.50%). In conclusion, the novel 
GenoFlow Test showed comparable clinical performance to LA test, and offers advantages of reduction in turnaround 
time and manpower. 
Keywords: HPV genotyping test, GenoFlow, Linear Array, Flow-through hybridization. 
INTRODUCTION 
  Mucosal HPV strains are categorized into high risk (HR) 
and low risk (LR) strains based on their association with 
cervical lesions. HR types are more frequently found in 
premalignant or malignant lesions, while LR types occur 
more frequently in benign ones such as condylomata 
acuminate [1]. In a study that included only high quality 
histological data, infection by HR HPV was demonstrated in 
99.7% of cervical carcinoma [2]. Although the majority of 
HPV infections can be cleared spontaneously, persistence of 
HR-HPV infection is a significant risk factor among women 
in the general screening population for the development of 
high grade cervical intraepithelial neoplasia and potential 
progression to cervical cancer [2-7]. Indeed, HR HPV DNA 
has been detected in 74% of the premalignant low-grade 
cervical intraepithelial neoplasia lesions and approximately 
84% of the high grade lesions [8]. On the other hand, 
persistent infection with the same HPV genotype has also 
been proved to associate with an elevated risk of developing 
high-grade preinvasive diseases such as dysplasia and 
ultimately cervical cancer [7, 9-11]. 
  Despite the prevalent application of Pap smear in some 
developed countries, cervical cancer remains one of the 
major female cancers [2], with estimates of 473,000 newly 
diagnosed cases and 253,500 yearly deaths worldwide [12]. 
Persistent HR-HPV positivity is related to an enhanced risk 
of developing premalignant disease and thus these cases 
should be closely monitored [13, 14]. HPV DNA testing has 
been shown to be more sensitive than cytology [13, 15-17],  
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and is therefore suggested to be useful in monitoring patients 
with treated cervical intraepithelial neoplasia [13, 18-20]. 
Several studies have further suggested that HPV DNA 
testing could improve the efficacy of population-based 
screening programs in detecting underlying lesions or their 
subsequent development, either when applied as an 
independent tool or as an adjunct to Pap smear [13, 14, 21-
23]. Indeed, the incorporation of HPV DNA testing into 
screening programmes and/or management of women with 
Atypical Squamous Cells of Undetermined Significance 
(ASC-US) has been suggested as guidelines in regions 
including Europe, USA, and Hong Kong [24-26]. 
  Assays targeting HPV viral DNA are commercially 
available in the market, which vary in running cost, hands on 
time, specificity and sensitivity. Some of the widely-used 
assays include the Hybrid Capture 2 (HC2) system (Digene 
Corporation, Gaithersburg, MD, USA), the AMPLICOR 
HPV Test (Roche Molecular Diagnostics, Branchburg, NJ, 
USA), the LINEAR ARRAY HPV Genotyping Test (LA; 
Roche Molecular Diagnostics, Branchburg, NJ, USA), and 
the INNO-LiPA HPV Genotyping (Innogenetics, Belgium). 
Neither HC2 nor the AMPLICOR HPV Test assay is capable 
of distinguishing specific genotypes, and they also lack the 
ability to identify infections involving multiple genotypes. 
Given the facts that 1) oncogenic potential varies among 
HR-HPVs [27]; 2) risk elevates with persistent infection of 
the same genotypes [7, 9-11]; and 3) HPV vaccines available 
could not prevent all types of HPV infections; HPV 
genotyping is needed in addition to generic screening for the 
presence or absence of the viruses. The LA and the INNO-
LiPA HPV Genotyping are both line probe assays capable of 
identifying 37 and 28 HPV genotypes respectively. 
However, these assays are rather expensive and they share 
the intrinsic problem of hybridization, that is, a relatively 
long turnover time of over 2 hours only from hybridization 
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  Based on these, we have developed GenoFlow HPV 
Array test kit (GenoFlow; DiagCor Bioscience, Hong Kong) 
for HPV genotyping. GenoFlow is a PCR-based assay that 
co-amplifies the human gene as an internal control to 
measure the integrity of the sample. This assay, by 
employing a membrane-based flow-through hybridization 
technology (US Patent number 5741647), identifies 33 HR 
and LR HPV viral genotypes (6, 11, 16, 18, 26, 31, 33, 35, 
39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 
66, 68, 70, 71, 72, 73, 81, 82, 84). A novel universal probe 
was also designed to capture HPV genotypes that were not 
included in the test panel in order to expand the viral 
coverage. It has indeed been shown that this universal probe 
has captured at least 5 other HPV viral subtypes in addition 
to the 33 genotypes included in the test panel. Through 
coupling with the flow-through technology platform, a 
satisfactory sensitivity and specificity has been warranted 
despite considerable reduction in the reagent cost and 
handling time [28]. Adding together the high throughput and 
superiority in handling time as compared to other genotyping 
assays available in the market, GenoFlow would potentially 
improve the efficacy of clinical diagnosis. The objective of 
this study is therefore to validate the performance in 
sensitivity and specificity of the GenoFlow by comparison 
with the LA. Our data showed that the GenoFlow attains a 
comparable performance in both sensitivity and specificity. 
The other feature of the GenoFlow kit (i.e. reduction in 
handling time and simultaneously detection of multiple 
samples) further support its possible role as a good product 
for HPV genotyping. 
MATERIALS AND METHODS 
Study Population and Specimen Collection 
  The studied cohort comprised archive samples of 100 
women whose cervical scrapes were collected in liquid-
based cytology medium (ThinPrep; Cytyc Corp., 
Marlborough, MA, USA) and sent to DiagCor Bioscience, 
Hong Kong, for HPV genotyping testing in September to 
October 2009. In order to increase the proportion of HPV 
+ve subjects so that the type specificity can be compared 
between the GenoFlow test and LA test, this study included 
a panel of HPV positive samples together with random HPV 
screening samples, making the total number of subjects be 
100. The cervical specimens were aliquoted into two aliquots 
for DNA extraction: one aliquot for GenoFlow test and one 
aliquot for LA test using the suggested extraction method of 
each genotyping test. 
GenoFlow Human Papillomavirus Array Test Kit 
  The GenoFlow test uses biotin-labeled primers and 
specific probes to detect 33 common HPV types (18 HR 
HPV types and 15 LR types, Table 1). In this study, DNA 
was extracted from the aliquot specimen using QIAamp 
DNA mini kit (Qiagen) according to manufacturer’s 
instructions. The extracted DNA was mixed with PCR 
reagent mix and DNA Taq Polymerase provided with the 
GenoFlow test kit and PCR-amplified using the thermo-
cycling condition stated in the manual. The amplicons were 
genotyped using Flow-through hybridization according to   
 
 
Table  1.  HPV Genotypes Detected by GenoFlow and LA 
Tests 
 
Detected in
a: 
Oncogenic Potential  HPV Type 
GenoFlow Linear  Array 
16 D  D 
18 D  D 
31 D  D 
33 D  D
 
35 D  D
 
39 D  D 
45 D  D 
51 D  D 
52 D  D
g 
53 D  D 
56 D  D 
58 D  D
 
59 D  D 
66 D
b  D 
68 D
b  D 
73 D  D 
81 D  D 
High risk 
82 D  D 
6 D  D 
11 D  D 
26 D
c  D 
40 D
d  D 
42 D  D 
43 D
  --- 
44 D
  --- 
54 D
e  D 
55 D
e  D 
57 D
f  --- 
61 D
d  D 
62 ---  D 
64 ---  D 
67 ---  D 
69 ---  D 
70 D  D 
71 D
f  D 
72 D  D 
83 ---  D 
84 D
c  D 
IS39 ---  D 
Low risk 
CP6108 ---  D 
a: D = detected. 
b – f: GenoFlow test does not distinguish between types 26 and 84, 40 and 61, 54 and 55, 
57 and 71, and 66 and 68, as each pair of genotypes is detected by the same dot on the 
membrane. 
g: The LA probe for genotype 52 does not distinguish 52, 33, 35 and 58, although the 
LA test contains specific probes for genotypes 33, 35 and 58. 
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manufacturer’s instructions. “Flow-through” technology 
involved hybridization, enzyme conjugation and colorimetric 
developed and intermittent washings, which can be finished 
in 35 min. A sample will be considered valid only if the 
hybridization control (for monitoring the success of 
hybridization), amplification control (for access of sample 
integrity or successful PCR reaction), and/or specific HPV 
type on the membrane were obtained. Positivity was shown 
by colored dots on the membrane, which was recorded by 
scanning of the membrane by flat based scanner. 
Linear Array HPV Genotyping Test 
  The LA test uses biotinylated primers to amplify the 
polymorphic L1 region of HPV genome (~450 bp) and 
human  -globin (for DNA integrity). It identifies 18 HR 
HPV types and 19 LR types (Table 1). The LA test in this 
study was carried out by a third party in order to rule out 
possible bias in this study. DNA was extracted from 
specimen aliquot by AmpliLute liquid medium extraction kit 
(Roche Molecular Diagnostics, Branchburg, NJ, USA). The 
PCR amplicons were denatured by denaturation solution and 
subjected to hybridization with a single LA HPV genotyping 
strip that was coated with HPV type-specific and human -
globin probes according to manufacturer’s instructions. The 
biotin-labeled amplicons hybridized to the probes only if the 
type-specific sequence matched the amplicons. The biotin-
labeled amplicons were detected by colorimetric 
development and the results were read visually by comparing 
the pattern of colored lines to the provided reference guide. 
Statistical Analysis 
  To compare the GenoFlow test and LA test, the studied 
cases were categorized into two groups: the HPV +ve and 
HPV –ve groups by each test. The agreement of the tests in 
the detection of HPV +ve cases was assessed by Cohen’s 
Kappa statistic, with values higher than 0.8 indicate excellent 
agreement. The Kappa value was calculated using an online 
program (http://faculty.vassar.edu/lowry/kappa.html). The 
sensitivity, specificity, false positive (+ve) rate, false 
negative (-ve) rate, and concordant rate of GenoFlow test 
were calculated according to the formulae in Table 3, using 
the results of LA genotyping test as reference. To further 
study the agreement of the test in detecting HR +ve cases, 
the cases were further categorized into three groups: the HR 
group, LR group and HPV –ve group by each genotyping 
test. A case was categorized into HR group if it showed any 
of the HR types; a case with multiple infections of both HR 
and LR types was also categorized into HR group. Cohen’s 
Kappa statistic was used to assess the agreement of both 
genotyping tests. 
RESULTS 
  The GenoFlow test and the LA test detect 33 and 37 HPV 
genotypes, respectively. Table 1 showed the genotypes 
detected by both tests. The concordance between the 
GenoFlow and LA tests in the detection of HPV infection is 
shown in Table 2. Among the 100 women tested, 57% were 
found HPV-positive by both tests and 38% were found HPV-
negative by both tests, with an overall agreement of 95% 
(Cohen’s Kappa = 0.896 [95% CI: 0.808-0.985]). Using the 
results of LA test as reference, the sensitivity (95.00%),   
 
specificity (95.00%), false positive rate (3.33%), false 
negative rate (7.50%), and overall concordance rate (95%) of 
GenoFlow test were calculated as shown in Table 3. The 
high Kappa value (0.896) and the high sensitivity and 
specificity illustrated the good agreement between 
GenoFlow test and LA test. 
Table 2.  Concordance Between DiagCor GenoFlow Test and 
Roche LA Test in 100 Samples 
 
No. of Samples GenoFlow Test 
LA Test 
Positive Negative 
Total 
Positive 57  3  60 
Negative 2  38 40 
Total 59  41  100 
Note: Cohen’s kappa = 0.896 (95% CI: 0.808-0.985). 
 
Table 3.  The Sensitivity and Specificity of DiagCor GenoFlow 
Test 
 
 Formula   
Sensitivity TP/(TP+FN)  95.00% 
Specificity TN/(TN+FP)  95.00% 
False positive rate  FP/(TP+FN)  3.33% 
False negative rate  FN/(TN+FP)  7.50% 
Concordance rate  (TP+TN)/(TP+TN+FP+FN)  95.00% 
Note: TP: true positive; TN: true negative; FP: true positive; FN: false negative. 
 
  Concerning the concordance between the kits in the 
overall infection profile, 29 samples were completely 
concordant cases that showed complete match of genotypes 
by both tests among the 57 samples found positive by both 
tests. The remaining 28 samples were compatible cases that 
involved multiple infections. The profiles resulted by both 
tests were shown in Table 4. 
  In order to assess the capability of the GenoFlow test in 
distinguishing HR and LR cases, the positive results of both 
tests are categorized into HR and LR groups, with HR group 
contained the samples showing any HR genotype. The 
concordance of the GenoFlow and LA tests is shown in 
Table 5, with a Cohen’s Kappa value 0.876 (95% CI: 0.787-
0.965). This indicated a good agreement between the tests, 
with a very slight decrease in Kappa compared to the value 
in Table 2 (Cohen’s kappa = 0.896, 95% CI: 0.808-0.985), 
showing that the capability of diagnosing high-risk HPV 
infection is similar for both tests. 
DISCUSSION 
  In this study, we have shown that the GenoFlow test and 
the LA test are highly congruent for the genotypes detectable 
in both assays, albeit with minor dissimilarities in 
compatible cases. The overall concordance of the two assays 
was 95%, with a Cohen’s Kappa value of 0.896, which 
indicated a good correlation. Among the 100 samples, 67 
were concordant cases that showed complete agreement, in  
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Table 4.  Compatible Cases in this Study 
 
HPV Genotypes 
Identifier 
GenoFlow Test  LA Test 
2 52  52*,  66 
3 40/61  40,  51 
5  16  16, 70  
8  6, 26/84, 51, 59, 82  6, 18, 39, 51, 59, 82, 84 
13  35  35, 52*, 62  
14  82  51, 82  
22  52, 81  40, 52*, 56, 66, 81  
23  43/44, 57/71  40, 62, 71 
26  35  35, 52*  
27  82  51, 82  
28  52, 66/68  26, 52*, 66 
29  43/44, 57/71, 81  55, 71, 81  
31  6, 40/61, 59  59 
35  58  16, 52*, 58  
36  52  52*, 62  
38  18  18, 39, 62  
41  70  54, 70  
48  11, 39, 53, 81  39, 53, 81 
49  39  39, 83  
58  58  52*, 58  
59  33, 53, 58, 59  35, 52*, 53, 58 
60 51  40,  51 
65  16, 52  16, 52*, 62  
66  58  52*, 58  
68  51, 53  39, 51, 53, 82 
70  33  18, 33, 52*, 58  
90  16, 33, 53, 66/68  16, 33, 52*, 66  
93  53  39, 53  
*: The 52 probe of LA test does not distinguish HPV 52, 33, 35, 58. 
 
Table 5.  Analysis of High-Risk and Low-Risk Cases 
 
GenoFlow Test 
 
High-Risk Low-Risk  Negative 
High-risk  49 1  1 
Low-risk  1  6 2 
L
A
 
T
e
s
t
 
Negative  2 0  38 
Note: Cohen’s Kappa = 0.876 (95% CI: 0.787-0.965). 
Results were further analyzed by categorizing into high risk and low risk 
cases. Grey boxes indicate cases with concordance between the two assays. 
 
which 29 positive cases were identically concluded by the 
two assays and the other 38 cases were HPV negative; 5 
samples were discordantly concluded. The GenoFlow test 
was able to identify HPV 16 and 18, which together caused 
about 70% cervical cancer [29, 30]; as well as HPV 58, 
which was prevalent in east Asia and especially in China 
[31-33]. 
  Cases that involved unique genotypes detected by either 
of the assays but not by both were defined as “compatible 
cases”. All of the 28 compatible cases involved multiple 
infections. GenoFlow test did not detect 17 genotypes in 26 
cases (sample number 2, 3, 5, 8, 13, 14, 22, 23, 26-29, 35, 
36, 38, 41, 49, 58-60, 65, 66, 68, 70, 90 and 93); but it 
detected 6 genotypes that were not detected by LA in 6 cases 
(sample number 23, 29, 31, 48, 59 and 90) (Table 4). 
Nevertheless, among the 26 cases that consisted of 
genotypes not detected by GenoFlow test, sample number 
26, 58 and 66 actually brought about ambiguity concerning 
the presence the HPV 52. The HPV 52* probe of LA test 
detected HPV 52, 33, 35 and 58, and the infection of HPV 
52 cannot be negated nor guaranteed with the positivity of 
either of the 33-, 35-, or 58- specific probes. Therefore, the 
possibility of these cases of having complete agreement 
between both tests could not be ruled out. These results 
(complete agreement between HPV profiles- 67%; 
compatible- 28%; discordant: 5%) were comparable to an 
earlier study comparing LA and another commercially 
available assay [34] (complete agreement between HPV 
profiles- 65.9%; compatible- 21.2%; discordant: 12.9%). 
Variations among genotyping results have been reported in 
many commercial kits or assays as reported in earlier studies 
[34, 35]. It has even been reported that the complete 
concordance of HPV infection profiles generated by the 
same LA assay was only 83% [36]. The complexity of 
assessing multiple genotypes has been addressed in earlier 
studies that biased amplification would possibly occur if 
certain genotypes are present in molar excess [35]. 
Nevertheless, it is important to identify whether such 
variation would lead to faulty diagnostic conclusions of HPV 
status, that is, whether patients with HR HPV infection 
would be classified as LR HPV infection, or vice versa. This 
study therefore further analyzed the results by separating the 
cases into HR and LR (Table 5). Among the 100 cases, 49, 6, 
and 38 cases were concordantly identified as HR, LR and 
negative respectively. Two cases were concluded by the 
assays with different risk levels (2%); 1 LA HR (1%) and 2 
LR (2%) case were concluded negative by GenoFlow test; 
and 2 GenoFlow test HR cases (2%) were concluded 
negative by LA test. This analysis resulted in a Cohen’s 
Kappa value of 0.876, which indicated a good correlation 
between the tests in delineating HR and LR cases. 
  The reliability of GenoFlow test was evidenced by its 
good correlation with LA test as indicated in this study. In 
consideration of the assay protocols, both the LA and 
GenoFlow test consist of four main processes: DNA 
extraction, PCR amplification of targeted sequences, 
hybridization of PCR products to specific oligonucleotide 
probes on a membrane, and colorimetric detection [34, 37]. 
Indeed, despite the reliability conferred, the relatively long 
turnaround time and manual operation are the common 
drawback of any assays that employ hybridization. For 
example, it has been estimated by a previous study that the 
hybridization process (i.e. excluding PCR) in manual LA test 
requires 180 min, of which incubation takes at least 107 min DiagCor GenoFlow and Roche Linear Array HPV Tests  The Open Virology Journal, 2010, Volume 4    173 
[38]. Flow-through system was developed to enhance the 
efficiency yet retain the reliability of hybridization technique 
in a simple operation setting. It has been estimated that with 
the application of the Flow-through system, the PCR and 
hybridization of HPV identification can be completed within 
3 hours [28]. 
  The recommended methods of DNA extraction of both 
tests make use of column extraction. The PCR of both tests 
requires less than 2.5 hours to complete when set according 
to respective manual of the kits. Nevertheless, the 
hybridization process of the tests requires significantly 
different duration because of the use of Flow-through 
technology. The incubation time in the hybridization process 
of GenoFlow test requires about 35 min, compared to LA 
test, which requires about 107 min according to its manual 
(Table 6). In addition, GenoFlow test facilitates aspiration of 
solution from 15 reactions at the same time by Flow-through 
technology while conventional methods require aspiration 
one by one reaction. The kits are also different in the number 
of solutions requiring fresh preparation, which would affect 
the ease of handling and hands-on time. All solutions 
provided with GenoFlow test are ready-to-use while 6 
solutions in LA test require fresh preparation before use 
from stock solutions provided. 
Table 6.  Incubation Times of GenoFlow Test and LA Test 
 
GenoFlow Test  LA Test 
Step  Time  
(min)  Step  Time  
(min) 
Pre-hybridization 2  Hybridization  30 
Incubation  5  Fast ambient wash  ~1 
Hybridization wash x3  ~1.5  Stringent wash  15 
Temperature changeBlocking ~10  Conjugate  30 
Enzyme conjugation  3.5  Fast ambient wash  ~1 
Temperature changewash x4  ~5  Ambient wash x2  20 
Detection 5  Citrate  5 
Wash x3  ~1.5  Substrate  5 
Stop 1  H2O 0 
Total ~35  Total ~107 
 
  The need of screening a large number of samples is 
observed in current market, especially due to the promotion 
in prevention of cervical cancer worldwide, such as the 
population-based screening programmes launched in at least 
13 European countries [39]. The capability of Flow-through 
system in processing 15 samples simultaneously further 
enhances screening efficacy by processing more samples at a 
short turnaround time and reduced manpower. 
  In conclusion, this study indicated that the GenoFlow test 
is an applicable and accurate assay for HPV genotyping in 
clinical samples. The performance of GenoFlow test is also 
comparable to LA test. Adding together the simplicity and 
reduced turnaround time associated to its protocol, 
GenoFlow test holds significant potential to serve as an 
affordable alternative in HPV diagnosis and screening 
programme. 
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